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S U M M A R Y
Background: The impact of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (ESBL-
EC) bacteraemia on outcome remains controversial.
Methods: A retrospective analysis of the prevalence, risk factors, clinical features, and outcomes of all
ESBL-EC bacteraemia in one French hospital over a 5-year period was performed. A case–control study
was undertaken: cases had at least one ESBL-EC bacteraemia and controls a positive non-ESBL-EC
bacteraemia.
Results: The prevalence of ESBL-EC bacteraemia increased from 5.2% of all positive E. coli blood cultures
in 2005 to 13.5% in 2009 (p < 0.003). CTX-M represented 70% of ESBL-EC bacteraemia strains, and strains
were not clonally related. On adjusted analysis, the only signiﬁcant risk factor for ESBL-EC bacteraemia
was a previous ESBL-EC colonization (odds ratio 11.3, 95% conﬁdence interval 1.2–107; p = 0.003). Initial
antimicrobial therapy was less frequently adequate in the ESBL-EC group (48% vs. 85%; p = 0.003). The
presence of ESBL-EC bacteraemia was not associated with a longer hospital stay (p = 0.088). Day
30 mortality was high, but not signiﬁcantly different in the two groups (30% vs. 27%; p = 0. 82).
Conclusion: The prevalence of ESBL-EC bacteraemia has been increasing dramatically. Previous
colonization with ESBL-EC was a strong risk factor for ESBL-EC bacteraemia. More inadequate initial
antimicrobial therapy was noted in the ESBL-EC group, but mortality and length of hospital stay were not
signiﬁcantly different from those of patients with non-ESBL-EC bacteraemia.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infections due to extended-spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae have become a major health§ This study was presented in part at the 50th ICAAC in Boston, September 13,
2010. Oral presentation; session 069/ESBLs and Carbapenem Resistance, slide
session.
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creativecommons.org/licenses/by-nc-nd/4.0/).problem. ESBL-producing Escherichia coli (ESBL-EC), especially of
the CTX-M type, have increased dramatically worldwide.1–3 Risk
factors for ESBL infection have been identiﬁed and include age,
comorbidities, poor functional status, recurrent urinary tract
infections, intensive care unit stay, prolonged hospital stay,
previous use of antibiotics, and colonization with ESBL.1,4 Studies
performed after the year 2000 have reported the risk of
bacteraemia in patients colonized with ESBL-producing bacteria
to range from 8.5% to 25%.5,6 Treatment options for infections due
to ESBL strains are limited, because resistance genes are harbouredious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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antibiotics.2 The impact of ESBL E. coli bacteraemia (ESBL-EC
bacteraemia) on mortality is controversial. Some studies have
shown that mortality is associated with inappropriate antimicro-
bial therapy, irrespective of ESBL production, whereas others have
reported an increased mortality due to ESBL.7–12
The aim of the current study was thus to assess the prevalence
and risk factors for ESBL-EC bacteraemia and to analyse their
impact on length of hospital stay and on day 30 mortality in
hospitalized patients.
2. Methods
Prevalence was studied using data from the Microbiology
Laboratory of Saint Louis Hospital, a 550-bed tertiary hospital with
major clinical activity in the areas of HIV, haematology, and
oncology. Data on all ESBL-EC and non-ESBL-EC bacteraemia from
January 2005 to December 2009 were collected. A retrospective
case–control study was then conducted, and all hospitalized adults
from January 2005 to December 2008 with at least one episode of
bacteraemia due to ESBL-EC were included for analysis. This study
was performed in accordance with the ethical standards described
in the 1964 Declaration of Helsinki. In this observational research,
no additional medical procedure was performed and all data were
retrieved from the medical charts of the treated patients. All
information was, however, given to the patients and, in accordance
with French legislation, patients could refuse the use of their
medical data. Baseline characteristics at the date of the ﬁrst
positive blood culture drawn, clinical and microbiological data,
antibiotic therapy, and outcomes were recorded carefully for each
patient.
Cases were deﬁned as adults with blood culture(s) yielding
ESBL-EC during the study period. In the case of several positive
ESBL-EC bacteraemia during the same infectious episode,
only the ﬁrst positive blood culture was considered for analysis.
For each case, one control was selected among hospitalized
patients with a positive non-ESBL-EC blood culture and
matched to the closest date of an ESBL-EC bacteraemia positive
deﬁning-case.
The following data were retrieved from the medical charts: age,
gender, underlying diseases and comorbidities (HIV, haemato-
logical malignancies, solid tumour, diabetes mellitus, solid organ
transplant), severity as assessed by the APACHE II score (the
Acute Physiology and Chronic Health Evaluation is a general
prognostic model for mortality calculated at admission), severe
neutropenia (absolute neutrophil count (ANC) <100/mm3),
current chemotherapy, antibiotic use during the past 3 months,
ESBL-EC colonization during the past 6 months, antibiotic
susceptibility of the isolated strain, initial antibiotic therapy,
length of hospital stay, and day 30 mortality (deﬁned as the time
from the ﬁrst positive blood culture until discharge or death).
Bacteraemia was classiﬁed as nosocomial, healthcare-related, or
community-acquired, as described previously.13 The source of
bacteraemia was considered to be urinary, catheter, digestive, or
respiratory when the strains recovered from the blood culture
and from the source were phenotypically similar. Rare locations
were classiﬁed as ‘other’, and when the portal of entry could not
be identiﬁed clearly, the source of bacteraemia was classiﬁed as
‘unidentiﬁed’.
An adequate ﬁrst antibiotic regimen was deﬁned as a regimen
containing at least one in vitro active drug, at the recommended
dose, and initiated within 24 h after the blood sample was drawn. If
one or more of these conditions was not fulﬁlled, then antimicro-
bial therapy was considered inadequate. Isolates were identiﬁed
using the API System (bioMe´rieux, Marcy l’Etoile, France). Strain
susceptibility to antibiotics was determined by disk diffusionmethod and interpreted according to the French Society for
Microbiology criteria with the 2008 susceptibility breakpoints
(ESBL-EC strains were interpreted as resistant to amoxicillin–
clavulanate, piperacillin–tazobactam, and to broad-spectrum
cephalosporins).14 ESBL production was detected by double-disk
synergy test between clavulanate and third-generation cephalos-
porins. ESBL type was identiﬁed by ESBL KPC Microarray (Check
Points, Wageningen, Netherlands), according to the manufac-
turer’s instructions. Previous colonization strains were also studied
using the same procedure. ESBL-EC colonization strains were
obtained by rectal swab during the 6 months prior to the onset of
bacteraemia for all patients in the non-ESBL-EC group and for 31
(76%) of the patients in the ESBL-EC group. ESBL-EC infection was
deﬁned as the ﬁrst positive ESBL-EC blood culture during the study
period. Genotype comparison between ESBL-EC bacteraemia
strains and colonization strains from the same patients was
performed using DiversiLab system software, version 3.3.40
(bioMe´rieux).15 Relationships between DiversiLab patterns were
designated as recommended in the manufacture’s guidelines:
different strains (similarity <92%) with three or more band
differences, or similar strains (similarity 92%) with two or fewer
band differences.
2.1. Statistical analysis
The trend in ESBL-EC bacteraemia prevalence over time was
compared with a Chi-square test for trend.
Baseline characteristics of the patients in the ESBL-EC and non-
ESBL-EC groups were compared by Wilcoxon signed-rank tests and
Liddell tests, accounting for the pair-matched design of the study.
The cause-speciﬁc proportional hazards model with death as a
competing risk was used for length of stay.
Conditional logistic regression was used for adjusted analysis.
The variables introduced into the multivariate analysis included
those with a marginal p-value of <0.15. APACHE II score was
included in the model as a continuous variable.
Since day 30 mortality of matched patients had no reason to be
correlated (matching only on the date of blood culture, with no
major changes in outcome over the study period), the outcome
analysis did not account for matching. It was nevertheless checked
that intra-pair correlation was negligible for outcome (intra-class
correlation coefﬁcients <0.0001). Risk factors for day 30 mortality
were analysed by logistic regression. Since there were only
23 deaths, only three variables were included in the model in
order to limit over-ﬁtting. Before including the variable ‘inade-
quate antimicrobial therapy’ into the model, an interaction with
ESBL-EC groups was tested. As a signiﬁcant interaction was
observed, results of the adjusted analysis on mortality are detailed
with the effect of inadequate antimicrobial therapy in the ESBL-EC
and non-ESBL-EC groups.
A sensitivity analysis was undertaken for patients in the ESBL-
EC group treated with piperacillin–tazobactam, according to the
current Comite´ de l’antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie (CA-SFM) and European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) 2015 guidelines (http://www.
sfm-microbiologie.org/.../casfm/CASFM_EUCAST_V1_2015.pdf):
ESBL strains were tested using the Etest method and considered
susceptible when the minimum inhibitory concentration (MIC)
for piperacillin–tazobactam was 8 mg/l. Patients were classi-
ﬁed as having received an adequate treatment if the strain was
susceptible and treatment initiated within 24 h after the ﬁrst
blood culture was drawn.
Analyses were performed using R statistical software, version
2.10.1 (R Development Core Team, Vienna, Austria). All statistical
analyses were two-sided and p-values less than 0.05 were
considered signiﬁcant.
Figure 2. Comparison by rep-PCR (DiversiLab, bioMe´rieux) of ESBL-producing
Escherichia coli strains responsible for bacteraemia and colonization in 10 patients
(indexed c). Red line: 92% similarity. To be similar, ESBL-EC bacteraemia strains and
corresponding colonization ESBL-EC strains (same patient number with an indexed
c) needed to have >92% similarity.
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The prevalence of ESBL-EC bacteraemia increased signiﬁcantly
from 5.2% in 2005 to 13.5% in 2009 (p = 0.003; Figure 1). From
2005 to 2008, 631 episodes of E. coli bacteraemia were recorded and
a ﬁrst episode of ESBL-EC bacteraemia was noted for 45 patients
(7.1% of ESBL-EC bacteraemia among E. coli bacteraemia). Medical
charts could be reviewed for 41 of the 45 patients, and were matched
with 41 controls with non-ESBL-EC bacteraemia.
Antibiotic resistance in the ESBL-EC and non-ESBL-EC groups
was observed, respectively, in 23% and 8% of cases with
gentamicin, in 5% and 0% with amikacin, and in 67% and 35%
with oﬂoxacin.
Thirty-three isolates responsible for ESBL-EC bacteraemia could
be characterized extensively: 21 strains produced CTX-M, seven
strains produced TEM-ESBL, and three strains SHV-ESBL. Two E. coli
produced two types of ESBL (CTX-M + TEM and CTX-M + SHV).
Eighteen CTX-M strains belonged to the group CTX-M1, three to
the group CTX-M9, one to the group CTX-M1 and TEM, and one to
the group CTX-M1 and SHV. Genotypic comparison between these
33 isolates did not show any epidemiological relationship,
suggesting a high variability among them (data not shown).
Thirteen patients had a positive ESBL-EC colonization strain.
Previous colonization strains were available for 10 of the 13 patients,
and a comparison between ESBL-EC bacteraemia strains and E. coli
colonization strains was undertaken (Figure 2). DiversiLab patterns
showed >92% similarity, with no band differences between the
ESBL-EC bacteraemia strain and the colonization strain in eight out
of 10 patients. For the two remaining patients, DiversiLab patterns
between ESBL-EC bacteraemia strains and E. coli colonization strains
(5/5c and 25/25c; Figure 2) showed 91% similarity (two different
bands) and 59% similarity (six different bands), respectively. ESBL
was typed for these two pairs of strains and only 25/25c had a
different ESBL type. Overall, the same ESBL type was seen in nine of
the 10 ESBL colonization strains studied.
Patient baseline characteristics, according to the study group,
are shown in Table 1. Patients had severe underlying conditions.
Indeed, haematological diseases were noted in 68% of cases
(28 patients) in the ESBL-EC group vs. 49% (20 patients) in the non-
ESBL-EC group (p = 0.046). Severe neutropenia (ANC <100/mm3)
was noted in 27% of patients overall, without a signiﬁcant
difference between the two groups (p = 0.39). Fifty-two percent
of patients overall had received chemotherapy during the past
month. The mean APACHE score was high and similar in the two
groups (p = 0.8). In the ESBL-EC and non-ESBL-EC groups, 83% andFigure 1. Prevalence of Escherichia coli ESBL bacteraemia among all E. coli
bacteraemia (%).71% episodes, respectively, were nosocomial or healthcare-related,
with a non-signiﬁcant difference between the groups (p = 0.27).
Risk factors for ESBL-EC bacteraemia are shown in
Table 1. While more patients in the control group had a urinary
portal of entry and more patients in the ESBL-EC group had
haematological malignancies, a more favourable outcome in
controls was not observed. On univariate analysis, having a
haematological malignancy (odds ratio (OR) 3.67, 95% conﬁdence
interval (CI) 1.02–13.1), antibiotic exposure during the past
3 months (OR 5.0, 95% CI 1.10–22.8), and an ESBL-EC colonization
(OR 12.0, 95% CI 1.56–92.3) were signiﬁcant risks factors for ESBL-EC
bacteraemia. On multivariate analysis, the only independent risk
factor for ESBL-EC bacteraemia was a known ESBL-EC colonization in
the last 6 months (OR 11.3, 95% CI 1.2–107; p = 0.035).
The initial antibiotic treatment was based on the association of
a broad-spectrum beta-lactam and an aminoglycoside or ﬂuoro-
quinolone in 72% of cases and 68% of controls (p = 0.81, Table 2).
Patients with ESBL-EC bacteraemia were less frequently treated
with an adequate antibiotic therapy compared to controls (48%
adequacy vs. 85%, respectively; p = 0.003) despite more carbape-
nem use in the ESBL-EC group (35% vs. 10%; p = 0.01).
The median length of hospital stay was not signiﬁcantly
different between groups: 15 days (interquartile range (IQR) 10–21
days) in the ESBL-EC group and 11 days (IQR 7–17 days) in controls
(p = 0.88) (data not shown).
Table 1
Baseline characteristics of patients with bacteraemia due to EBSL-EC or non-ESBL-EC and related risk factors for ESBL-EC bacteraemia
ESBL-EC Non ESBL-EC Univariate analysis Multivariate analysis
(n = 41) (n = 41) OR (95% CI) p-Value OR (95% CI) p-Value
Age, years, median (IQR) 54 (42–65) 56 (48–72) 0.98 (0.95–1.01) 0.13 0.98 (0.95–1.02) 0.31
Female gender, n (%) 14 (34) 13 (32) 1.12 (0.43–2.92) >0.99
APACHE II score, median (IQR) 18 (13–22) 18 (15–22) 1.00 (0.94–1.06) 0.80
Solid organ transplant, n (%) 2 (5) 0 (0) Inf (0.19–Inf) 0.50
Haematological malignancy, n (%) 28 (68) 20 (49) 3.67 (1.02–13.1) 0.046 2.81 (0.55–14.4) 0.22
Solid tumour, n (%) 5 (12) 9 (22) 0.43 (0.11–1.66) 0.39
Severe neutropenia (ANC <100/mm3),
n (%)
13 (32) 9 (22) 2.00 (0.60–6.64) 0.39
Chemotherapy in the past month, n (%) 22 (54) 21 (51) 1.12 (0.43–2.92) >0.99
HIV, n (%) 6 (15) 11 (27) 0.44 (0.14–1.44) 0.27
Diabetes mellitus, n (%) 0 (0) 2 (5) 0 (0–5.32) 0.50
Healthcare-related or nosocomial
bacteraemia, n (%)
34 (83) 29 (71) 0.27
Source of bacteraemia, n (%) 0.16
Urinary 7 (17) 15 (37) 0.33 (0.11–1.03)
Catheter 4 (10) 2 (5) 2.00 (0.37–10.9)
Digestive 15 (37) 11 (27) 1.50 (0.61–3.67)
Respiratory 2 (5) 2 (5) 1.00 (0.14–7.10)
Other 3 (7) 0 (0) Inf (0.41–Inf)
Unidentiﬁed 10 (24) 11 (27) 0.88 (0.32–2.41)
Antimicrobial therapy in the past
3 months, n (%)
37 (95) 29 (72) 5.00 (1.10–22.8) 0.039 2.33 (0.44–12.2) 0.32
Previous ESBL colonization, n (%) 13 (32) 2 (5) 12.0 (1.56–92.3) 0.003 11.3 (1.19–107) 0.035
ESBL, extended-spectrum beta-lactamase; EC, Escherichia coli; OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range; ANC, absolute neutrophil count.
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controls (p = 0.82). Risk factors for mortality according to the
groups studied are presented in Table 3. The ﬁrst model tested the
effect of ESBL-EC adjusted only for the APACHE score and no
signiﬁcant effect of ESBL-EC on mortality was noted (OR 1.23, 95%
CI 0.36–4.23). The second model was adjusted for APACHE score
and initial treatment adequacy. Since an interaction was observed
between treatment adequacy and ESBL-EC, results took into
account having an adequate or inadequate initial treatment
separately. Mortality was studied in the group with an initial
adequate treatment (OR 2.99, 95% CI 0.59–15.2) and in the group
with an initial inadequate treatment (OR 0.074, 95% CI 0.005–1.19),
both adjusted for the APACHE score. In both groups, the effect of
ESBL-EC adjusted for the APACHE score and initial treatment was
not signiﬁcant. On adjusted analysis, a higher APACHE score was
signiﬁcantly associated with a higher mortality rate in both
models.
In the sensitivity analysis, ﬁve patients treated with piper-
acillin–tazobactam in the ESBL-EC group were classiﬁed as having
had an adequate treatment after taking into account the current
breakpoints (MIC value for piperacillin–tazobactam 8 mg/l forTable 2
Initial regimen administered for patients with bacteraemia in the ESBL-EC and non-
ESBL-EC groups
Initial antimicrobial treatment ESBL-EC
(n = 40)
n (%)
Non-ESBL-EC
(n = 40)
n (%)
Univariate
analysis
p-value
Piperacillin–tazobactam 11 (28) 15 (38) 0.47
Third-generation cephalosporin 16 (40) 15 (38) >0.99
Carbapenem 14 (35) 4 (10) 0.01
Aminoglycosides 23 (57) 22 (55) >0.99
Fluoroquinolones 6 (15) 11 (28) 0.18
Vancomycin 12 (30) 5 (12) 0.12
Other 6 (15) 6 (15) 0.74
None 0 (0) 2 (5) 0.50
Association with aminoglycosides
or ﬂuoroquinolones
29 (72) 27 (68) 0.81
Adequate antibiotic therapy 19 (48) 34 (85) 0.003
ESBL, extended-spectrum beta-lactamase; EC, Escherichia coli.susceptible strains) and the delay between the ﬁrst blood culture
and ﬁrst antibiotic regimen. Two of the ﬁve patients died before
day 30 and three were still alive at day 30. In this sensitivity
analysis, patients in the ESBL-EC group still had less adequate
treatment (p = 0.049), with no difference in day 30 mortality in the
adjusted analysis (Supplementary Material, Tables S1 and S2).
4. Discussion
In this study, a dramatic increase in the prevalence of ESBL-EC
bacteraemia was observed, with a prevalence that doubled in
4 years. This increase in resistance has also been reported in recent
studies involving either immunocompetent or immunocompro-
mised patients.8,10,16 In Europe, the Antimicrobial Resistance
Surveillance Network (EARS-Net) showed that the proportion of
reported E. coli isolates resistant to third-generation cephalospor-
ins (proxy for ESBL-EC) increased signiﬁcantly during the 2006–
2010 period, with a resistance rate for invasive E. coli infections in
France and the UK in 2010 of 7.2% and 8.3%, respectively.
More than 70% of patients (cases and controls) had nosocomial
or healthcare-related E. coli bacteraemia, and, as described in
previous studies, ESBL-EC strains were predominantly CTX-M
strains (70%).
In contrast to other studies on bacteraemia due to ESBL-EC
reporting urinary tract as the primary infection site, the source of
bacteraemia was unknown in about 25% of cases and was mainly of
digestive origin in the remaining cases studied here. The baseline
characteristics of the population involved in the present work
(36 neutropenic patients (44%), including 22 cases (27%) with
severe neutropenia) may explain this discrepancy.
Regarding risk factors for ESBL-EC bacteraemia in a matched
control study, having a haematological malignancy, prior exposure
to antibiotics in the past 3 months, and previous colonization with
ESBL-EC strains were independent risk factors on univariate
analysis, while only colonization remained a risk factor on
multivariate analysis. Of note, all patients previously colonized
had received antibiotics in the past 3 months.
The similarity between colonizing strains and strains responsi-
ble for bacteraemia was studied and it was found that nine out of
Table 3
Adjusted analysis of the impact of ESBL-EC on Day 21 mortality
DAY30 mortality OR (95% CI) p
First model: model without the variable inadequate
antimicrobial therapy
ESBL-EC
non ESBL-EC
1.23 (0.36;4.23)
1
0.74
Apache score 1.28 (1.13;1.45) <0.0001
Second model: model with the variable inadequate
antimicrobial therapy (Interaction with ESBL: p = 0.025)
Adequate antimicrobial therapy:
- and non ESBL-EC
- and ESBL-EC
1
2.99 (0.59;15.2)
reference
0.18
Inadequate antimicrobial therapy:
- and non ESBL-EC
- and ESBL-EC
30.3 (2.30-399.2)
2.25 (0.29;17.7)
0.009
0.44
Apache score (per unit) 1.33 (1.15;1.53) <0.0001
ESBL, extended-spectrum beta-lactamase; EC, Escherichia coli; OR, odds ratio; CI, conﬁdence interval; APACHE, Acute Physiology and Chronic Health Evaluation.
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Nevertheless, no deﬁnitive conclusions can be drawn due to the
small number of strains that were available for analysis, although
this could be an argument for screening of ESBL colonization in
immunosuppressed patients, particularly in neutropenic patients,
to help deﬁne the empirical therapy in the case of fever. This differs
from a single study on ESBL-EC colonization and bacteraemia in
neutropenic patients, which found that colonization did not appear
to have any signiﬁcant clinical relevance.17
In the present study, despite signiﬁcantly more inadequate
probabilist treatment, there was no signiﬁcant increase in
mortality or length of hospital stay in patients with bacteraemia
due to ESBL-EC. There were slightly more patients with a urinary
portal of entry in the control group and more patients with
haematological malignancies in the ESBL-EC group. Despite these
favourable characteristics in the control group, a more favourable
outcome was not observed for controls. Unsurprisingly, in the
adjusted analysis, a higher APACHE score was signiﬁcantly
associated with a higher mortality rate.
In the sensitivity analysis, ﬁve patients in the ESBL-EC group
were reclassiﬁed as treated with an adequate antibiotic therapy,
according to the current susceptibility breakpoints for ESBL strains
(EUCAST/CA-SFM, 2015). In this sensitivity analysis, results with
regards to inadequate treatment and day 30 mortality did not
change when considering the recent guidelines.
In a meta-analysis including 15 studies, ESBL-EC bacteraemia
was associated with higher mortality after adjusting for con-
founding factors (OR 1.51), and treatment inadequacy was the
explanation for the higher death rate.18 Very recently, a multi-
centre cohort study found inadequacy as a risk factor for death on
multivariate analysis, but not in patients with no severe sepsis or
shock.19 The same level of treatment inadequacy was observed in
the present study, but without a signiﬁcant impact on mortality in
the adjusted analysis on ESBL-EC and APACHE score.
The mortality (30%) observed in the present study is relatively
higher than reported elsewhere and may also probably be
explained by the haematological conditions of the population
studied.7,19 Patients in both groups had severe underlying diseases
and a critical clinical condition at baseline, as attested by the
APACHE score. The probability of death in patients with an initial
APACHE II score of 18 is 29%, which corresponds to the mortality
rate observed in this study. The same results were found in the
study published by Garcı´a Herna´ndez et al. on ESBL-EC bacter-
aemia with more inadequate initial treatment, but with a mortality
statistically associated with the severity of underlying diseases and
critical severity of illness at onset, but not with the presence of
ESBL-producing strains.9 In seriously affected patients, as de-
scribed in the present study, the real impact of ESBL-EC
bacteraemia on the overall mortality is difﬁcult to assess.
The length of stay, rarely studied elsewhere, was not affected by
the antibiotic resistance of E. coli responsible for bacteraemia.However the high mortality and the small number of patients
included may explain the absence of impact of resistance on length
of stay.
Some limitations of this study should be acknowledged. First it
was a retrospective study performed at a single institution. Second,
it is underpowered due to the small size of the effective.
In conclusion, it was found that the prevalence of ESBL-EC
bacteraemia increased dramatically throughout the study period,
with a large predominance of CTX-M strains that were not clonally
related. Previous colonization with ESBL-EC was the only signiﬁ-
cant risk factor for ESBL-EC bacteraemia on multivariate analysis.
ESBL-EC bacteraemia was not associated with a prolonged length
of hospital stay. Overall mortality was high in the immunosup-
pressed population studied. Despite more inadequate initial
antimicrobial therapy in patients with ESBL-EC bacteraemia in
this study, there was no signiﬁcant increase in mortality rate.
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